Tazeen Ahmad
BofA Securities, Research Division

My pleasure to have our next presenting company, Denali Therapeutics. Sitting up here on stage with me is Alex Schuth, who is, of course, Chief Operating Officer as well as CFO, double duty. Alex, thank you for making the, hopefully, short trip over to see us in the desert today.

Alexander Schuth
Co-Founder, CFO, COO & Secretary

All right. Well, again, thank you, Tazeen, for inviting us for a fantastic conference. But really also thank you for following us for many years now and the always very thoughtful commentary. So much appreciated. So great to be here today. It's a special time for us at Denali.

As you know, we just had our first drug approved in March, big transition for us. Big moment for Denali, but also a big moment for the Hunter syndrome community. And I think importantly, also a really big moment for the whole field of blood-brain barrier transport. So looking forward to the conversation and going deeper on all of those topics.

Tazeen Ahmad
BofA Securities, Research Division

Yes. So maybe let's start off with your first commercial launch. How is that going so far? And I've been asking everybody to pronounce the name of their drug so that we're saying it correctly.

Alexander Schuth
Co-Founder, CFO, COO & Secretary

So this one here, if you think about Star Wars, it's [ Avlaya]. So once you think about Star Wars, you can get -- you also think about the Himalayas and then you can also remember. So the drug's name is AVLAYAH. And it is, of course, indicated for the treatment